OSP3 @CRI

Thursday, March 21st to Saturday, March 23rd 2019

Third Global

OPEN SOURCE PHARMA

Conference

CRI

DRUID

Science License Community

OSP3 @CRI PROGRAM

Thursday, March 21st

12:00pm to 2:00pm
Registration
Where? PC Security
Alegoria Icebreaker A&W
Where? Lounge

1:00pm to 2:00pm
Icebreaker - Three Bears
Each participant comes up with 3 ideas
1 small, 1 medium, and 1 big, for OSP
Where? Lounge

2:00pm to 2:30pm
Welcome to CRI and OSP3
by Ariel Lindner
by Jaykumar Menon
Where? Learning Centre

2:30pm to 3:00pm
Intro to OSP
Bernard Munos
OSP concepts, history, future, communication
Where? Learning Centre

3:00pm to 5:00pm
Participant Introductions
Flash Talks
Where? Learning Centre

5:00pm to 6:30pm
Three Urgent Questions by Matthew Todd
1. Who's going to invest in OSP?
2. Why can't someone take what you've done and run with it?
3. Surprise question
Where? Learning Centre

6:30pm to 7:30pm
Evening Reception
Where? Lounge

OSP3 @CRI PROGRAM

Friday, March 22nd

8:30am to 9:15am
Breakfast
Unveiling of Art Installation by Eric Anderson
Where? Lounge

9:15am to 9:30am
Welcome & Recap
Where? Amphitheatre

9:30am to 10:45am
1st Session
Open R&D: Across the stages
- Nadine Bongaerts - CRI
- Tomasz Sablinski - Transparency Life Sciences
- Sitta Sittampalam - National Institutes of Health (NIH)
- Matthew Todd - Open Source Malaria (*moderator*)

Where? Amphitheatre

11:00am to 12:00pm
2nd Session
Open Source Communities and Modes of Organization
- Anshu Bhardwaj - CRI
- Bruce Bloom - Cures Within Reach (*moderator*)
- Samir K Brahmachari - Open Source Drug Discovery (OSDD)/ AcSIR
- Alice Williamson - University of Sydney

Where? Amphitheatre

12:00pm to 1:30pm
Lunch in House
Screening of *The Gift* by Robin McKenna
Where? Lounge

1:30pm to 2:45pm
Breakout Session / Cluster Groups
Participants break out into small groups on various themes, and then summarize in plenary session
Where? 1 quai des Célestins, 75004 Paris

2:45pm to 4:00pm
3rd Session
OSP business models and sustainability
- Ellen 't Hoen - Medicines Law and Policy
- Bernard Munos - FasterCures
- Benjamin Perry - DNDi (*moderator*)
- Guy Rouleau - Montreal Neurological Institute and Hospital

Where? Amphitheatre

4:00pm to 4:30pm
Break
Where? Lounge

4:30pm to 5:00pm
OSP & Education:
by Lee Hartwell, Nobel Laureate
Where? Amphitheatre

5:00pm to 6:15pm
4th Session
Can Blockchain enable OSP?
- Keith Elliston (*moderator*) - i2b2/tranSMART
- Niclas Nilsson - LEO Pharma
- Paul Kohlhaas - Molecule Foundation

Where? Amphitheatre

6:15pm to 6:45pm
Crowdsourced Resources Exercise
Where? Lounge

6:45pm to 7:30pm
Evening Reception
Where? Lounge

OSP3 @CRI
PROGRAM

Saturday, March 23rd

8:30am to 9:00am
Breakfast
Where? Lounge

9:00am to 9:15am
Welcome & Recap
Where? Learning Centre

9:15am to 10:30am
5th Session
Can we develop an OSP license?
And other IP questions
- Keith Elliston - i2b2/tranSMART/ Open Source Pharma Foundation
- Linda Kahl - BioBricks Foundation
- Andy Updegrove - Gesmer Updegrove LLP (*moderator*)

Where? Learning Centre

10:30am to 11:25am
Group Participant Reflections
Where? Learning Centre

11:25am to 11:30am
Conclusion
Where? Learning Centre

OSP3 @CRI
Participants

Eric
ANDERSON

Eric Anderson is an artist and writer living in Rochester, MN. His art installations have been featured in exhibits and public works projects in collaboration with the Smithsonian Museum of Natural History, the National Institutes of Health's National Human Genome Research Institute, Mayo Clinic, Destination Medical Center and the Rochester Art Center.

A graduate of the Iowa Writers' Workshop, his writing has appeared in Granta, American Letters & Commentary, Columbia Poetry Review, and elsewhere. As the 2018-2019 Artist-in-Residence at the Open Source Pharma Foundation, he is designing an installation for their 2019 conference at the Center for Research and Interdisciplinarity at the University of Paris, France.

Urmi
BAJPAI

Associate Professor
Department of Biomedical Science at Acharya Narendra Dev College, University of Delhi

Deputy Dean
Research at the Research council in University of Delhi, 2017-2018

Ph.D. in Microbiology
University of Delhi, South Campus

First teacher in-charge of department of Biomedical Science and has 20 years of teaching experience. She pioneered the undergraduate research program in the college since 2006. She is recognized as Ph.D. supervisor and has been the Principal Investigator of several research projects funded by DBT, CSIR-OSDD, DU, DST (IEDC & SERB) and has established a well-equipped molecular biology laboratory in the college.

Her team has been working towards finding new TB drugs with Mur enzymes in the cell wall biosynthesis pathway of Mycobacterium tuberculosis as the drug targets and exploring the potential of mycobacteriophages and their lytic enzymes (Endolysins) as the source of anti-bacterial agents. She is the co-founder of International Bacteriophage Research Consortium (IBRC) with Open Health System Laboratories (OHSL), USA

AWARDS

- *Indian National Science Academy (INSA)Teacher Awardee 2018.*
- *'Excellence Award for Teacher in Service in College', given to highly deserving individuals who have rendered exemplary service to the University of Delhi (2017).*
- *Meritorious Teacher Award given by Govt. of NCT of Delhi in 2014.*

ANTI-MYCOBACTERIAL DRUG DISCOVERY LABORATORY at ANDC
http://andcollege.du.ac.in/sites/default/files/College%20website%20InfoUB20Oct.2018.pdf

Bryn BELLOMY

Bryn Bellomy is an entrepreneur and software engineer with many years of experience working with and contributing to open source communities and projects.

In the past, he has helped to found ventures in digital media, music, and renewable energy. As a software engineer, his specialties include decentralized technologies, peer-to-peer networking, blockchains and smart contracts, and high-performance web 2.0 platforms.

His most recent venture, Axon, is «Github for science» — a platform for open source scientific research and development. Axon (http://axon.science) seeks to replicate and recontextualize the many successes of the open source software movement for fields such as computational chemistry and medical device development.

Mostapha BENHENDA

Mostapha Benhenda is founder of Startcrowd, an online lab specialized in AI for Pharma, at various stages of the drug development pipeline.

He learnt coding and machine learning with online courses, and with Startcrowd, he is contributing to take online education to the research level. Mostapha got a PhD in Mathematics from the University of Paris 13, and is an alumni of the Ecole Normale Supérieure of Paris.

Anshu BHARDWAJ

Did Masters in Biotech followed by Ph.D. in Life Sciences (Computational biology) at Centre for Cellular & Molecular Biology, Hyderabad, India, in 2008. I then served as one of the founding PIs for Open Source Drug Discovery Project where I conceived & developed protocols for crowdsourcing drug discovery. Currently I am a senior scientist with the CSIR-Institute of Microbial Technology and Assistant Professor with AcSIR.

I enjoy working with anyone who has interest in addressing public health challenges. I have a large network on students (who I call SciTechtives) with whom I co-develop tools for data analysis (genotype-phenotype correlations, in silico drug discovery, comparative and functional genomics).

My primary research interest is to develop tools to address antimicrobial resistance (AMR). In CRI, I am working on genomic signatures to identify priority pathogens. In addition, I am also developing a gaming app for creating awareness on AMR. Both these objectives align with the Global Action Plan on AMR.

For the project, I will utilize my experience in crowdsourcing, functional & comparative genomics & computational drug discovery and the wonderful ecosystem of CRI.

Marc BIANCIOTTO

After my Ph.D. in Theoretical Chemistry at Université Paul Sabatier in Toulouse (France), I have been working for 18 years as a Drug Designer in the pharmaceutical industry.

As such, I have been exposed to numerous Drug Discovery projects in which I have been involved in most steps of the Drug Discovery value chain. I am also an enthusiast and heavy user of Free and Open Source Software, and passionate about bringing more efficiently new therapeutic options to the patients.

Anneke BLACKBURN

A/Prof Anneke Blackburn (BSc (Hons), PhD).

I am a translational research scientist in the field of Cancer Metabolism and Genetics at The John Curtin School of Medical Research (JCSMR), Australian National University (ANU) and The Canberra Hospital (TCH). With a broad background including biochemistry, pharmacogenetics of drug metabolising enzymes (ANU), genetic susceptibility to breast cancer (UMass, Amherst, MA, USA), targeting metabolism in cancer (ANU), and running a small investigator-initiated clinical trial for cancer treatment (TCH).

My career has included the support of a NHMRC Howard Florey Centenary Fellowship (2002-2005), NHMRC R.D. Wright Career Development Award (2006 – 2011), and receiving the inaugural Tony Ayers Prize for Excellence in Translational Medicine, College of Medicine, Biology and Environment, ANU (2014). I am a member of the Centre for Oncology Education and Research Translation (CONCERT), Sydney, and kConFaBConsortium for research into familial cancers.

I am also an educator, and have also created a course "Hallmarks of Cancer" for third year science students at the ANU. I am interested to see if we can productively harness the undergraduate "crowd" to contribute to OSP research projects. I established and convene the JCSMR Consumer Representative Panel for Cancer Research, where scientists and community representatives engage in two-way exchange of ideas and experiences to help shape our research projects.

I am now looking to work out how to get the drug I have researched for over 20 years, dichloroacetate, to market without a patent.

Bruce BLOOM

Dr. Bruce Bloom is CEO of Cures Within Reach, the leading global non-profit saving lives by unleashing the untapped potential of human approved drugs, devices, diagnostics and nutraceuticals, by testing new uses for them to quickly deliver safe and affordable treatments and cures for diseases that have no currently effective therapy.

Cures Within Reach uses CureAccelerator ® , the only online repurposing research collaboration platform, to bring together clinicians, researchers, funders, and industry to create and conduct proof of concept repurposing clinical trials.

Dr. Bloom is an Ashoka Social Entrepreneur Fellow, the Patient Advisory Board Chair for the Institute for Translational Medicine, board member of the Drug Discovery Center and Chair of the Cancer Center Advancement Advisory Boards at the University of Illinois Chicago, member of the Vanderbilt Institute for Clinical and Translational Research External Advisory Board, and is on the Science Advisory Boards of Rediscovery Life Sciences, the Dr. Ralph and Marian Falk Medical Research Trust Awards Programs, the Findacure Fundamental Disease Charity, the Rare Disease Research Hub of the Westchester Biotech Project, OneThree Biotech, and Healx, LTD, and a member of the editorial board of ASSAY and Drug Development Technologies.

Nadine BONGAERTS

Nadine Bongaerts is a PhD student in synthetic biology at the Centre for Interdisciplinary Research in Paris where she works on the development of engineered E. coli strains with TB drug targets as a cost-effective, rapid and easy-to-scale tool for antibiotic discovery.

She previously studied in the Netherlands and holds a bachelor and master degree in Life Sciences & Technology from the University of Leiden and TU Delft. In addition to her PhD, she is actively bridging the world of science with business though her role as vice-president of the international non-profit organisation Hello Tomorrow for deep tech innovation.

Samir K. BRAHMACHARI

Prof. Samir K. Brahmachari is the Academy Professor of Academy of Scientific and Innovative Research, Former Professor of Biophysics, Indian Institute of Science, Bangalore and Chief Mentor of Open Source Drug Discovery.

He is also the Chief Mentor, Health Technology Innovations for ACCESS Health International, Inc. He is the Founder Director of CSIR – Institute of Genomics and Integrative Biology (1997-2007) and former Director General of CSIR India, the largest publicly funded industrial research organization in the world and Secretary, DSIR, Government of India (2007-2013). He conceptualized and implemented the functional genomics research in India and the Indian Genome Variation Project. He is the chief architect of open source drug discovery project in India. He presently mentors several startups in Genomic Medicine and Big data analytics.

He is the recipient of many national and international awards including Shanti Swarup Bhatnagar prize. He is an elected fellow of The World Academy of Sciences, the European Society of Preventive Medicine and member of all four National Academies of Science & Engineering, India.

Tanusree CHAUDHURI

Tanusree is fuelled by her passion towards applying the knowledge of computational biology in the field of Drug discovery and genetics.

She has obtained both her bachelor's degree in Biotechnology and master's degree in Bioinformatics from The West Bengal University of Technology in 2006 and 2008 respectively. In the beginning of her carrier, she has worked as research fellow at "Bose Institute, Kolkata" and obtained a strong knowledge on evolutionary genetics. She also worked as lecturer in some of the well-known colleges in Kolkata in the field of Bioinformatics. After moving to Bangalore, she joined "The Oxford College of Engineering, Bangalore" as Assistant professor in the field of Bioinformatics. She has been working there till 2018. There she guided many students in different project works and M. Tech thesis in Bioinformatics domain.

She also obtained TATA-CSIR women fellowship for 6 months from Jan 2014-June 2014, where she contributed in upgrading Avogadro software to establish a novel, GUI based, open source platform to make drug discovery cost effective and affordable. Her hunger for knowledge and determination to turn information into action has contributed towards most recent change in her carrier from a full time faculty to a full time researcher at "The National Institute of Advanced studies, Bangalore". Currently, she is pursuing her long-term goal and her childhood dream by dedicating her time completely towards research work in neglected disease like Epilepsy

Karmen
CONDIC-JURKIC

After obtaining master degree in chemistry at the University of Zagreb, Croatia, I pursued a PhD in computational chemistry and biophysics awarded by Friedrich Alexander University in Erlangen, Germany, followed by 4 years of postdoctoral experience in Australia at the University of Queensland and Australian National University.

My research was primarily focused on proteins and their structure-function relationship, from enzymes to transmembrane proteins. During my postdoc period, I developed a prototype for a cloud-based repository for sharing molecular simulations, which deepened my general interest in open science and digital infrastructure supporting it.

In April, I will start my position as a project manager for Open Force Field Initiative - a collaborative open source / open data / open science project between pharmaceutical industries and academics to improve the accuracy of the physical models and methods used in simulations of biochemical systems and drug design.

Julia
DANIEL

Julia Daniel is a master's student in Computer Science at Stanford University, California, where she also completed a Bachelor's degree in Human Biology.

She has completed a range of projects related to infectious disease, front-end design, medication adherence, education, and public policy. Throughout her time studying and practicing software engineering in Silicon Valley, open-source culture has been integral to these projects.

She is currently working on launching a socially-minded career at the intersection of public health and computer science.

Anjana
DHAR KOUL

Anjana Dhar Koul is a Medical Doctor with 11+ years of experience and proven expertise in clinical trial study activities and all aspects of medical monitoring and medical review of listings and safety data. Therapeutic areas include infectious diseases (HIV,TB,HCV), Rheumatoid arthritis, Oncology.

Acted as Medical Monitor/Advisor for all aspects of assigned clinical trials, including management of trial programs. Performed medical support to the clinical project teams and pharmacovigilance in all related steps of case processing and periodic reporting. Supported biometrics functions with monitoring, data management, and communication plans. Actively participate in the preparation and review of essential documents related to clinical studies (synopsis,protocol)

Liesl EICHHOLZ

Liesl Eichholz is a blockchain and open source software advocate with a background in organisational design, law, and political science. Liesl became involved the open source space with the goal of developing socially impactful new methods of human organisation and coordination.

She is currently pursuing these goals in the context of the pharmaceutical industry as Growth Strategy Lead at Molecule. Her experience includes roles covering mechanism design, cryptoeconomics, business development, and strategy, with previous positions at ConsenSys, Centrality, and Roche, among others.

Keith ELLISTON

Keith Elliston is a scientist and entrepreneur in the for profit and non profit biomedical space. He was a co-founder and the Executive Director of the i2b2/tranSMART Foundation, a 501c3 non profit open-source, open-data foundation focused on realizing the promise of precision medicine.

Keith cofounded the tranSMART Foundation, was its CEO from 2013-2017, and managed its merger with the i2b2 Foundation. Previously he was the VP of Systems Biology at CHDI (a Huntington's disease foundation), where he oversaw a budget of $60M, and implemented a systems biology-based preclinical drug discovery program.

Keith spent 12 years in the Pharmaceutical industry with Merck and Bayer, and another 10 years in the Biotech industry as CSO of Gene Logic, and CEO of Viaken and Genstruct/Selventa.
He has been the Founder and CEO/Executive Chairman of several new startup companies in the areas of biomedical computing and artificial intelligence (Axiomedix, Ingentium, PSertain Technologies, etc.), and has served as an advisor to numerous venture capital firms, including Atlas Ventures, Oak Investment Partners and Flagship Ventures, as well as leading biotech, healthcare and AI companies.

Nicole FOTI

Nicole Foti is currently working toward a PhD in Medical Sociology from University of California San Francisco. Her academic background is in Biology and Gender Studies, and she worked at an HIV/AIDS nonprofit prior to her current position. Her interests are at the intersection of biomedical science and social and political structures.

ABOUT OPEN INSULIN

We're a team of biology enthusiasts located in the Bay Area with collaborators around the world who believe that insulin should be available to anyone who needs it. So, we're developing the first simple, economical, and open source protocol for producing insulin. We hope our research will be the basis for decentralized, low-cost production of this life-saving drug and pave the way for more open source pharma projects and more competition and dynamism in the business of treating and curing diseases, especially metabolic diseases like diabetes which are behind a large portion of morbidity and mortality in the world today. Our approach centers the production of insulin at a small scale, seeking to enable production of pharmaceuticals at the community level.

The project was founded by a group of volunteer scientists at Counter Culture Labs in Oakland, CA in 2015. Counter Culture Labs is a community of scientists, tinkerers, biotech professionals, hackers, and enthusiastic fans of sharing knowledge who have banded together to create an open community lab — a fully stocked biology wet-lab built in the spirit of 'hacker spaces' and 'maker spaces' to support anyone who wants to pursue a question. The lab is part of the burgeoning global DIY science movement with a focus on open source science.

You can read more about the project at
http://openinsulin.org/press/

Stephen FRIEND

Having spent some time interested in how to predict and treat various conditions from the vantage point of a physician-scientist I am now intrigued by the diversity of individual trajectories taken by people in that phase where symptoms arise and shift in many chronic conditions.

Realising that wearables such as smart-phones, smart-watches and smart-rings etc... offer ways to explode the dimensions of individual assessments while doing so semi-continuously it feels an appropriate time to ask whether we can yet move beyond the current world of «medical alchemy» where within the existing medical industrial complex most medical care is given by anointed guilds of experts (MDs) using paternalistic orders to be followed. What would it take to build communities where participants interested in building knowledge by each other for each other would share health data and insights as a means to find others whose paths would be informative for certain others. Unlike in the past, we are testing if we might use as AI driven approach to finding similar individual paths built up from data and insights on very large numbers of participants.

Current Efforts

We are designing studies to test what are the fundamental unknowns in making individual forecasts for symptom changes and in empowering people to co-pilot their own chronic medical conditions.

A major current interest is focused on tracking momentary and allostatic stress as detected by wearables and how they might be used to help forecast symptom changes in diverse conditions such as pregnancy, menopause, migraines, MS, and Crohn's disease.

Recent talk - Alan Turing Lecture
https://www.youtube.com/watch?v=P3zbg-l-UkI

More info available at the nonprofit 4YouandMe
https://www.4youandme.org

Bareket
GELBHART

Bareket Gelbhart attended the Technion, Israel Institute of Technology, from where she holds her Bachelor degree in Chemistry with Organic Chemistry as the principal subject.

She is fluent in Hebrew and English and can converse in Italian. Bareket posses advanced knowledge of Microsoft Word, Excel and PowerPoint.

She resides in Ticino, Switzerland with her family, from where she travels across the globe regularly for work.
Bareket is a passionate cook and a die hard football fan.

MORE INFO
https://gelbhart.com/the-team

Hans HAGEN

Hans Hagen was trained as a parasitologist and medical entomologist at the Liverpool School of Tropical Medicine, UK, and the University of Tübingen, Germany, where he received his PhD in 1992. During his research career in the field of infectious tropical diseases, he undertook substantial field research on the transmission of river blindness, in mainly Francophone West and Central Africa. Hans has worked in a number of laboratories in Brazil, USA, France, Sweden, Germany, Hungary, and the UK. In 1999, Hans decided to switch careers, and started his new post at the Wellcome Trust, mainly working with science communities outside the UK (India, Central Europe, sub-Saharan Africa, and Latin America).

In 2006, Hans was recruited by the Royal Society, to develop the Society's capacity strengthening programme for sub-Saharan Africa. This programme was initially focussed on Ghana and Tanzania, resulting in the Leverhulme - Royal Society Africa Award scheme, which was successfully launched in October 2008. This was followed by a more ambitious pan-sub-Saharan Africa programme, launched in November 2012, after obtaining substantial funding from the Department for International Development (DFID), and the ground work that led to the launch of the Future Leaders - African Independent Research (FLAIR) Fellowships in 2018. In 2014, he was promoted to Head of Grants of the Royal Society. From 2015 to 2017, Hans worked as Chief Operating Officer for Cambridge University Health Partners before joining Institut Pasteur as Deputy Director of the Centre for Global Health and Chargé de Mission at the Department of International Affairs, in October 2017.

Deputy Director
Center for Global Health

Chargé de Mission
La Direction Internationale
Institut Pasteur, Paris

Leland HARTWELL

Lee Hartwell, PhD, led a research team at the Genetics Department, University of Washington, from 1968 to 1997 studying the genetic control of cell division in yeast.

He was President and Director of the Fred Hutchinson Cancer Research Center from 1997-2010. He received the 2001 Nobel Prize in Physiology or Medicine.

Currently, Dr. Hartwell does research in education at Arizona State University, with the goal of improving teacher education in sustainability and science education.

Other honors include the Albert Lasker Basic Medical Research Award, the Gairdner Foundation International Award, the Alfred P. Sloan Award in cancer research, the Genetics Society Medal of Honor, and the Cal Tech distinguished alumni award. He is a member of the National Academy of Sciences.

Director
Pathfinder Center

Director
Biodesign Institute,

Director
Arizona State University

Mélanie HEARD

I was trained in philosophy (Ecole Normale Superieure, Paris). I hold a PhD in political science from Sciences Po (Paris). My main research interests focus on public health, health policy and the decision-making process.

My PhD was about French HIV/AIDS policies. I have worked for 10 years in high-level health policy-making at the local and national level ; as a member of the health ministry's team from 2013 to 2016, I contributed to some major decision-making processes regarding French health policy, including the making of the 2016 health law.

Today, coming back to research activities, I intend to focus on participatory approaches in health policy, studying deliberative citizen assemblies and the concepts of patients expertise and collective wisdom regarding public choices and health policies. I teach philosophy of education in CRI Paris.

Martin HETU

Martin Hetu is a PhD student at HEC Paris. His research focuses on the impact of intellectual property rights on innovation. More specifically, he studies the effect of gene patents on drug development at the international level using quantitative analysis methods.

Prior to his PhD studies, he completed a M.Sc. in International Studies at the University of Montreal and obtained a law degree (B.C.L./LL.B.) from McGill University. He also conducted research on ethical, legal and social implications of genomics within the Centre of Genomics and Policy at McGill University.

UCA JALEEL

Dr. UCA Jaleel is a Principal Scientist at the OSPF-NIAS Drug Discovery Lab, NIAS IISc Campus Bangalore. He leads a team of drug discovery researchers who focus on various aspects of cheminformatics, including machine learning and AI-based analysis of neglected tropical diseases like TB, Malaria, and Leishmaniasis.

His primary focus is in the application of machine learning and AI models in the medicinal chemistry data sets. He successfully applied ANN based machine learning models on the inconclusive molecules of the beta-lactamase bioassays of Mycobacterium tuberculosis. As a Principal Investigator of the «Cheminformatics for Neglected Diseases Project» for Open Source Drug Discovery CSIR Govt of India, he was instrumental in building as well as managing the crowdsource and machine learning solutions for various issues in the tropical disease research. His major contribution includes the solutions for the issues related with higher dimensional analysis and extractions of principal features of the in silico designing of machine learning models. His work at CSIR OSDD research unit at Indian Institute of science Bangalore could establish the successful modelling of semiconducting properties by machine learning and higher dimensional correlations of various kinds of datasets.

As a big believer of open source, Jaleel supports the crowd and cloud source way of conducting research for early-stage drug discovery. Before joining OSPF in 2015, Jaleel worked for 12 years for a diverse range of organizations, including the Council of Scientific and Industrial Research (CSIR) Open Source Drug Discovery (OSDD) research unit at IISc, Bangalore; and the UGC Centre for Cheminformatics, Malabar Christian College in Calicut, India. In this role, he was responsible for guiding and supervising researchers in cheminformatics.

Linda KAHL

Dr. Linda Kahl is a strong advocate for biotechnology in the public interest. She currently serves as Senior Counsel for the BioBricks Foundation, where she works with academic research institutions, industry leaders, government agencies, funding organizations and other stakeholders to ensure the open and ethical engineering of biology for all people and the planet. She also serves on the committee for Safeguarding the Bioeconomy with the US National Academies of Sciences, Engineering, and Medicine, as lead writer for the International Genetically Engineered Machine (iGEM) Foundation, as Senior IP counsel for The Lens, and on the advisory boards for Artists United and Open Reagents.

Originally trained as a research scientist, Linda received her BS in Biology from UCLA and her PhD in Cell Biology and Biochemistry from Princeton University. She completed postdoctoral studies in genetics at UC Berkeley, where she held fellowships from the American Cancer Society, the Damon-Runyon Cancer Research Foundation, and the Howard Hughes Medical Institute. Linda received her JD, magna cum laude, from Santa Clara University School of Law, earning the High Tech Law Certificate with an emphasis in intellectual property law. She is a licensed patent attorney with bar admission to practice law in California and before the U.S. Patent and Trademark Office.

Prior to becoming an attorney, Dr. Kahl founded and directed SciScript Communications, a consulting firm that helps biotechnology companies, pharmaceutical companies, and academic research organizations communicate their findings in technical reports, clinical study protocols and peer-reviewed journals. of Cambridge Centre for Science and Policy. After earning her law degree Linda became a legal scholar at Stanford University, where she led the Ownership, Access, Sharing, and Innovation Systems (OASIS) project for Synberc, a Synthetic Biology Engineering Research Center funded by the U.S. National Science Foundation. Recently, Dr. Kahl was appointed as a Policy Fellow at the University of Cambridge and as a Herbert Smith Freehills Visiting Scholar at the University of Cambridge Faculty of Law.

Dr. Kahl writes and lectures on topics relating to biotechnology law and policy, and has been an invited speaker at numerous venues, including conferences of the World Economic Forum, World Health Organization, OECD, European Science Open Forum, Global Bio Summit, and the U.S. National Academy of Sciences' Committee on Science, Technology and Law. Empirical data derived from Dr. Kahl's work is helping shape the policies and practices of government, funding, and community organizations that impact the regulation, patenting, and licensing of foundational biotechnologies.

Along with her professional interests, Linda enjoys cooking for her family, camping in the Pacific Northwest with her husband Jeff, and has recently published her first children's book – Linda Lilly's Day.

Paul KOHLHAAS

Paul Kohlhaas is a blockchain entrepreneur with a passion for open source utility networks.

After studying economics, he started Linum Labs a blockchain development studio and worked as business development director at ConsenSys, pioneering real-world implementations in self-sovereign identity with uPort in Switzerland.

A profound passion for the systemic macroeconomic problems in the pharmaceutical industry led him to found Molecule Protocol, a software system to accelerate innovation in the pharmaceutical industry by creating open markets for chemical intellectual property.

Peter KOLB

After studies in Biochemistry and Theoretical Chemistry at the University of Vienna and Karolinska Institute, I did my Ph.D. in Computational Biochemistry with Amedeo Caflisch at the University of Zurich. My work there focused on fragment-based docking for kinase ligands as well as chemoinformatic method development. After a short continuation as a postdoc in the same group, I joined the lab of Brian K. Shoichet at the University of California, San Francisco. This coincided with the publication of the structure of the first pharmacologically relevant G protein-coupled receptor, a unique opportunity to carry out one of the first studies of xray-structure-based ligand design for this protein class. Besides docking to GPCRs, I worked on the prediction of substrates for enzymes of unknown function, and have as such been contributing to the Enzyme Function Initiative.

From April 1, 2011 until October 2016, I was an Emmy Noether Junior Group Leader at Philipps-University Marburg. From May 2013 until April 2017, I was chairing COST Action CM1207 «GLISTEN: GPCR-Ligand Interactions, Structures, and Transmembrane Signalling: a European Research Network», which connected more than 210 scientists from 31 European countries.

In March 2015, I was awarded the «Innovation Prize in Medicinal/ Pharmaceutical Chemistry» by the Medicinal Chemistry sections of the Society of German Chemists (GDCh) and the German Pharmaceutical Society (DPhG). This was followed by the «Silver Jubilee Award» of the Molecular Graphics and Modelling Society (MGMS) in November of the same year.

Since October 2016, I am Professor of Pharmaceutical Chemistry, funded by the Heisenberg programme of the German Research Foundation DFG.

Thomas
LANDRAIN

One of the pioneers behind the DIYbio (Do-it-yourself Biology) and Open Science movements and communities. He founded in 2009 La Paillasse in Paris, the first French open lab who became one of the largest ones in the world. Helped hundreds of open health, environmental and social projects that impacted thousands of people worldwide.

Helped bootstrap synthetic biology in France as an academic researcher. He co-founded the first French iGEM team in 2007. He co-built the first dedicated research lab to synthetic biology in 2008 where he started his PhD. He published 9 peer-reviewed papers during that time.

Decided to leave academia to focus entirely on building and experimenting with alternatives to a rusty academic system for the production of open knowledge and innovations, through La Paillasse first and now with Just One Giant Lab (JOGL).
Co-Founded in 2015 the synthetic biology company PILI who is bringing the first sustainable alternative solution to petrochemistry for the fabrication of dyes at industrial scale by using fermentation. PILI is now a 17 strong-employees R&D company and has raised more than $4M.
Member of the French National Digital Council where he pilots the working group on ecological transition.
Ambassador at the iGEM Foundation, organising the largest open biotech competition in the world (>6000 participants every year).

Speaks worldwide on open research, DIYbio, collective intelligence and future of communities, science and innovation at gathering such as TEDx, Lift, OuiShareFest, MIT CommunityBio, CollaborAmerica Brazil, FoundersForum UK, MakerFaire Shenzhen and AfricaOSH.

Ariel LINDNER

Ariel Lindner is a research director at the French National Institute of Health and Medical Research (INSERM), co-founder and Director of Research of the Centre for Research and Interdisciplinarity and co-director of its AIV M.Sc. program.

He graduated from the 'Amirim' interdisciplinary program with a major in Chemistry (Hebrew University, Jerusalem) and received my M.Sc. and Ph.D. from the Weizmann Institute of Science for work on enzyme models, antibody conformational changes and directed evolution. After a research period on protein structures at the Scripps Institute (California, USA), and postdoctoral work in Paris on bacterial genetics, he integrated in the Evolutionary Systems Biology team (now: SEED: Systems Engineering and Evolution Dynamics) at INSERM.

His research interests revolve around applying Physical, Chemical and Systems/Synthetic Biological approaches to study variability between clonal individuals. Major contributions in past 5 years include publications in Nature, Science, Cell and PNAS journals for which he is an occasional reviewer. He coordinates the Citizen CyberLab European project (citizencyberlab.eu), a national research agency interdisciplinary consortium and takes part in the Axa foundation Chair on Longevity. He is also involved in research at the interface between art & science.

Amanda McPHERSON

Amanda McPherson is an advisor, board member, writer and college lecturer on technology, marketing and open source issues. Most recently she was the Chief Marketing Officer and Vice President of Developer Programs for the Linux Foundation, a worldwide non-profit that advances and protects the Linux operating system and other open source software projects. As a founding executive of the Linux Foundation, she led growth of the business to a $50m a year entity and established the brand as one of the most trusted names in software.

For twenty years, she has occupied a unique position in the technology world—the intersection of open source software and marketing. She has incubated and designed open source governance for many projects, and created and curated software conferences including LinuxCon, ContainerCon and CloudOpen.

Currently, she is an advisor on marketing strategy, open source governance and organizational development for venture-backed start-up companies and global public health projects, with special interest in how open source governance models can impact projects utilizing blockchain technologies.

Amanda is also a published fiction writer, with an MFA in creative writing, and currently lives in Salt Lake City, UT.

Jaykumar MENON

An international human rights lawyer, scholar, and social entrepreneur, Jaykumar Menon fancies himself a giant killer. He is currently a Senior Fellow at the Harvard Global Health Institute, a Visiting Scientist at the Harvard School of Public Health, and a Research Fellow at the Centre for International Sustainable Development Law, which is based at McGill University. His research, teachings and practice focus on innovative approaches to realizing basic human rights for a billion or more people. He is a founder and the chair of the Open Source Pharma Foundation, which aims to generate affordable new cures in areas of great health need and to create a new open source innovation model for drug discovery, and which is currently Phase 2B clinical trials for a new adjunct therapy for tuberculosis. He is also a founder of The India Nutrition Initiative, which is developing salt double-fortified with iron and iodine ("DFS"), to help address the world's the most widespread form of malnutrition, iron deficiency, which afflicts 2 billion people, disproportionately women and children. DFS is currently reaching over 10 million people.

Previously, Jaykumar led the international development program at the X PRIZE Foundation, an innovation group dedicated to achieving «radical breakthroughs for the benefit of humanity.» As a human rights lawyer at the New York City-based Center for Constitutional Rights, he won a string of victories in high profile cases. His work includes representing student leaders of Tiananmen Square against the ex-Premier of China, helping win a $4 billion judgment on behalf of victims of the Bosnian genocide, freeing a man from death row in Indiana, helping represent the family of Nigerian environmental activist Ken Saro-Wiwa against Royal Dutch Shell, and hunting through the prisons of New York for the real killer to help free an innocent man (David Wong) serving life for murder, as the 15th lawyer to take up the case. As a scholar, he has written articles in top peer-reviewed international human rights law journals and reference books. He has also co-founded a tech company with seven-figure revenues and worked as a strategist at McKinsey. He is a life member of the Council on Foreign Relations. Jaykumar is a winner of the William Rogers Award, the Brown Alumni Association's highest honor, given to one graduate annually. Jaykumar holds a JD and a Master of International Affairs from Columbia University along with a BA degree and one year of medical school at Brown. Through his creative and strategic approach, he hopes to bring about large-scale social change in the communities he works with.

Dusan MISEVIC

After graduating from Caltech in mathematics and biology, Dusan got his Ph.D from Michigan State University in evolutionary biology, working with Rich Lenski and Charles Ofria. He did a short postdoc at ETH in Switzerland with Sebastian Bonhoeffer before coming to CRI in 2009 as a postdoc in the Evolutionary and Systems Biology team of the INSERM U1001.

Currently Director of Research Affairs at CRI, he is charting the course for CRI Research, designing and organizing the Advanced Workshops, structuring and executing the recruiting of the Research Fellows, and mentoring the Fellows. Previously he was the Scientific Coordinator for the undergraduate program Frontiers in Life Science at CRI. His background is in evolutionary and computational biology.
participating in char

Alice MOTION

Dr Alice Motion is a chemist and science communicator based at The University of Sydney. Her research focuses on open science and Science Communication, Outreach, Participation and Education (SCOPE). Finding ways to connect people with science and to make research more accessible is the overarching theme of Alice's interdisciplinary research.

Alice is the founder of the Breaking Good project – a citizen science project that aims to empower high school and undergraduate students to be active researchers in projects that will improve human health. In 2016, students working as part of the Breaking Good pilot project recreated the price-hiked medicine Daraprim for just a few dollars, sparking an international conversation about access to medicine and demonstrating the impact that students can have when they are involved in real research.

Originally from the North West of England, Alice completed her PhD at The University of Cambridge, where she worked with colleagues to develop two new chemical reactions. Alice moved to Australia to take up a position as the principal synthetic chemist for OSM, who are pioneering an open source drug discovery project and are trying to prove that science is better and more efficient when all data and results are shared. The team do not patent any of their findings; instead they publish all of their work online in real time so that anyone can access their research.

Alice is recognised as a leading international science communicator. In 2015, she was named as one of ABC RN and UNSW's Top 5 Under 40 in recognition of her passion for sharing science stories. She was the RACI Nyholm Lecturer for 2017/18 and a finalist in the 2017 American Association for the Advancement of Science (AAAS) Early Career Award for Public Engagement with Science. Alice is the co-host of the ABC Science podcast, Dear Science, and has been the host of a weekly science slot on FBi Radio's breakfast show since June 2015.

(publications prior to 2019 are under the name Alice E Williamson)

Bernard MUNOS

Ariel is a research director at the French National Institute of Health and Medical Research (INSERM), co-founder and director of Research of the Centre for Research and Interdisciplinarity and co-director of its AIV M.Sc. program.

He graduated from the 'Amirim' interdisciplinary program with a major in Chemistry (Hebrew University, Jerusalem) and received my M.Sc. and Ph.D. from the Weizmann Institute of Science for work on enzyme models, antibody conformational changes and directed evolution. After a research period on protein structures at the Scripps Institute (California, USA), and postdoctoral work in Paris on bacterial genetics, he integrated in the Evolutionary Systems Biology team (now: SEED: Systems Engineering and Evolution Dynamics) at INSERM.

His research interests revolve around applying Physical, Chemical and Systems/Synthetic Biological approaches to study variability between clonal individuals. Major contributions in past 5 years include publications in Nature, Science, Cell and PNAS journals for which he is an occasional reviewer. He coordinates the Citizen CyberLab European project (citizencyberlab.eu), a national research agency interdisciplinary consortium and takes part in the Axa foundation Chair on Longevity. He is also involved in research at the interface between art & science.

Niclas NILSSON

Dr. Niclas Nilsson is spearheading an initiative to use Open Innovation at the core of drug research with focus on driving innovation with external collaborations at LEO Pharma, a pharmaceutical company in Denmark focusing on dermatology and inflammatory skin disease. Prior to setting up the LEO Pharma Open Innovation platform, Niclas was heading the molecular pharmacology department.

With passion for pushing boundaries and as a strong believer in inter-disciplinary science he is now exploring how to disrupt traditional R&D to promote mutually benefits and more open ways to collaborate across traditional barriers and borders.

Niclas holds two degrees, PhD in medical sciences and MSc in molecular biology, with a focus on and drug discovery. The current role as heading the R&D Open Innovation initiative focuses on strategic development and operational implementation of open innovation to catalyze the use of external research and fuel the drug pipeline, expand disease understanding and boost corporate innovation with opportunities that otherwise wouldn't happen.

Niclas Nilsson, MSc, PhD
Head of Open Innovation, Research, LEO Pharma

Ole F. OLESEN

Dr Ole F. Olesen is Director of International Cooperation at the European & Developing Countries Clinical Trials Partnership (EDCTP). EDCTP is a non-profit organization, supported by the European Union and 30 countries in Africa and Europe, with the aim of supporting the clinical development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as neglected infectious diseases.

Ole studied at the universities of Aarhus, Denmark and Cambridge, UK, as well as at Copenhagen Business School, and holds a PhD degree in Molecular Biology and an HD degree in international economics. Ole has worked for 10 years in the pharmaceutical industry as group leader and later as Global Project Director for pre-clinical and clinical development of vaccines and injectables.

He has considerable work experience in conducting and managing large international projects on pharmaceutical product development. Before joining EDCTP, Ole was Principal Scientific Officer for Global Health at the European Commission's Directorate-General for Research & Innovation, and responsible for research in tuberculosis, neglected infectious diseases and vaccinology.

Ole is also affiliated professor at the Department of Public Health at Copenhagen University.



Benjamin PERRY

Benjamin Perry has broad medicinal chemistry experience across a variety of therapeutic areas including infectious disease, inflammation, pain, neurodegeneration & psychiatry.

His scientific interests include creation of strategic research collaborations and evaluation of novel technologies for drug discovery, with a particular focus on AI and novel screening technologies. Currently Ben is responsible for Open Innovation Discovery at Drugs for Neglected Disease initiative (DNDi), a not-for-profit research organization based in Geneva Switzerland.

Previously Ben held senior research positions at a variety of drug discovery companies including Genkyotex SA, Addex Therapeutics SA and UCB Pharma. He is cofounder of AiDD SA and MPC Therapeutics SARL. Ben holds a PhD in organic chemistry from Imperial College London and an MBA from IE Business School, Madrid.

Colin
PILLAI

Prof. Colin Pillai is the Founder at CP+ Associates GmbH (Switzerland) and CEO at Pharmacometrics Africa NPC (South Africa). Both companies are social ventures that develop scientific capability in low and middle income countries (LMIC), focusing on healthcare via the drug discovery and development sciences.

Colin is a clinical pharmacologist who undertook his training in Durban, South Africa. He has previously worked at the corporate headquarters of Novartis and Roche in Switzerland and has a specialist interest in the application of non-linear mixed effects models to pharmacokinetic-pharmacodynamic data across a wide range of therapeutic areas. He has undertaken various leadership roles within the pharmaceutical industry (Pharma) which have in turn contributed both to the internal and external acceptance of applying mathematical models to decision-making in drug development.

His most recent Pharma role involved establishing programmes enabling the sharing of scientific expertise and infrastructure with researchers and institutions in low- and middle income countries (LMIC).

Colin has held teaching, research and management positions at the Universities of Durban-Westville and Witwatersrand. He acquired his clinical and research experience in hospital and community pharmacy and as a consultant with the SA Medical Research Council's Tuberculosis Research programme, where he ran a unit conducting Phase 1 clinical trials. Pillai continues to maintain active academic links with numerous institutions in Africa, including via honorary professorships and board member status. He has been a senior advisor on capacity development and training programmes for global health to the Bill and Melinda Gates Foundation since November 2017.

Websites: www.cpplusassociates.org; www.pmxafrica.org
Email: colin@cpplusassociates.org
Twitter: @colpil

Nibedita RATH

Nibedita Rath is Scientific Director of the Open Source Pharma Foundation. She has more than eighteen years of scientific research experience both in industry and academia including IVY League, Premier Indian Institute, Biotech, Government undertaking and in non-profit organizations. She has experience in the interface of chemistry and biology, and she has played a key role in evaluating projects that includes strategy, synthesis, screening, structure-activity relationship (SAR) analyses, medicinal chemistry design. She has worked in multidisciplinary drug discovery projects in therapeutic areas like metabolic disorder, oncogenes and infection.

As a Functional Head in a biotech company, she was instrumental in building as well as managing the Chemical Synthesis Lab and Biochemical Screening division. Her major contribution includes taking nutraceuticals from bench to market as a food supplement and playing a key role in establishing a virtual Hepatotoxicity model for a client.

Her work as a Postdoctoral Research Scientist in MCRC, UPENN focused on identification of transcription factors in the formation and differentiation of the mammalian lung and vascular system. Her work at Drexel focused on molecular and functional dissection of BRCA1 and ELK1 Tumor Suppressor Genes in breast, ovarian and prostate cancers.

Her work at the Indian Institute of Science focused on complexation behavior of Ru(II) with nitrogen-based biheterocycles and phosphine derived ligands and analyses of their X-ray crystal structures and also studied their catalytic properties. She obtained her PhD in Chemistry from Utkal University, Orissa in 1999. She is a Gold Medalist and conferred with Best Graduate in the year 1992 and holds all India rank in GATE-1994.

She is leading a number of scientific programmes in OSPF - Generic Drug Repurposing , Knowledge Base, Knowledge Graph for Generic Drugs, Tuberculosis, , to name a few. Additionally, she is leading the effort of developing and exploring new strategic partnership and also managing communications and initiatives with OSPF key partners.

Guy ROULEAU

Over the last 25 years, Dr. Guy Rouleau and his team have focused on identifying the genes causing several neurological and psychiatric diseases, including autism, amyotrophic lateral sclerosis, hereditary neuropathies, epilepsy and schizophrenia, as well as providing a better understanding of the molecular mechanisms that lead to these disease symptoms. Among Dr. Rouleau's main achievements are his contribution to the identification of dozens of disease- causing genes and his discovery of new mutational mechanisms.

Dr. Rouleau has published nearly 800 articles in peer-reviewed journals and has been quoted more than 65 000 times (Google Scholar). He has supervised more than a hundred students at the Masters, PhD and Post-doctoral levels in addition to receiving numerous awards for his contribution to science and society.

Director,
Montreal Neurological Institute and Hospital

Chair, Department of Neurology and Neurosurgery,
McGill University

Chairholder, Wilder Penfield Chair in Neuroscience,
McGill University

Director, Department of Neuroscience,
McGill University Health Center (MUHC)

Chief, Division of Molecular Diagnostics
OPTILAB Montreal-MUHC

Contact
Dr. Guy Rouleau
Director, Montreal Neurological Institute and Hospital
3801 University Street, Office 636
Montreal, Quebec H3A 2B4
Tel: 514 398-2690
Email : guy.rouleau@mcgill.ca
Montreal Neurological Institute and Hospital: www.theneuro.com

William SCOTT

Dr. Scott got his bachelor's at Williams College, doctorate at UCLA, and did postdoctoral work at Rockefeller University and Caltech. He then joined Eli Lilly, working for 27 years in drug discovery and the development of new research technologies. He holds patents in the areas of enzyme inhibition, anti-cancer agents, Alzheimer's treatments, monoclonal drug conjugates, protein-drug linkers, solid-phase synthesis equipment, and amide coupling reagents.

While at Lilly Dr. Scott taught part time at Butler University and IUPUI. In 2002 he moved to a Research Professor position at IUPUI where he currently teaches, conducts research, and publishes on a wide variety of topics. He has a special interest in educating students in the drug discovery process and the skills required.

The overall focus of Professor Scott's current research is the development of simple, inexpensive equipment, and combinatorial synthetic methodologies to enable students to quickly and reproducibly make large numbers of molecules as potential drug leads for "orphan" and neglected diseases. At IUPUI he has developed a concept called "Distributed Drug Discovery" (D3) that involves chemistry undergraduates at multiple institutions throughout the world in this distributed process. D3's synthetic chemistry component is most developed. It has been implemented at sites in Russia, Spain, the Czech Republic, Cuba, Puerto Rico and Poland, along with six academic institutions in the continental United States. He has also presented lectures on Distributed Drug Discovery in Barcelona, Oxford, Geneva, Basel, Prague, Krakow and Lublin (Poland), as well as at multiple schools in the US. Dr. Scott recently developed a D3 compatible biology assay to enable a coupled D3 chemistry and biology lab in which students make and identify new potent inhibitors of P. aeruginosa growth.

Research Professor
Department of Chemistry and Chemical Biology
Indiana University-Purdue
University Indianapolis (IUPUI), Indianapolis, Indiana, USA

Anne-Marie SHAND

Anne-Marie Shand is the Director of Product Strategy at Taylor & Francis, where she is responsible for the development of new products and for building new business models. She has worked in product management, in both B2B and B2C markets, for over 15 years. Projects of note have included developing apps with Aardman Animations, managing large science publishing programmes, and in 2012 and 2016 respectively, working with the Wellcome Trust to design and deliver two large scale scientific public engagement projects which each engaged with over 5m school-aged students.

Anne-Marie lives near Oxford in the UK with her husband and two children. She was born in Bristol in England, to a French mother and and an English father, and it was because of their hard work that she is bilingual in English and French. She holds a BA in International Relations, a PGCE in Primary Education and a Masters' in Creative Digital Media.

G. Sitta SITTAMPALAM

Senior Advisor to the Director National Center for Advancing Translational Sciences (NCATS),
National Institutes of Health (NIH), Bethesda, MD, USA

Dr. Sittampalam is currently a Senior Advisor to the director at the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), Bethesda, MD, USA. He joined NCATS in 2011 as Project Manager for The Rare & Neglected Diseases (TRND) Program. In his current position (since 2014) works closely with NCATS director and senior administration in identifying and implementing publicprivate partnerships with academics, government and pharmaceutical and biotechnology organizations internationally.

He spent 23 years in discovery and development of biotherapeutics and small molecule drugs at Eli Lilly & Co, Indianapolis, IN., followed by 4 years as a tenured professor of Pharmacology, Toxicology and Therapeutics at the University of Kansas Medical Center, investigating rare cancers and tumor tissue engineering for drug discovery. During this period, as the Deputy Director of the Institute of Advancing Medical Innovations (JAMI) he also focused on moving mature, basic biomedical research into therapeutic development for commercialization. In his current position, he is the recipient of several NCATS/NIH Director's Awards for public-private partnerships and translational science collaborations in the USA and Japan.

He has served as a reviewer in NIH and other scientific grant review panels for drug discovery and stem cell research. He is currently Editor-in-Chief of the Assay Guidance Manual (NLM/ NCBI eBook), and in the scientific advisory boards of Science Translational Medicine. He has served on the editorial boards of sever journals, and past services include Scientific Advisory Boards of Science Exchange Inc., Organovo Holdings LLC., and Stemina Biomarker Inc. He was also the past President (2003-2004) and a member of the Board of Directors (1997-2000) at the Society for Bio molecular Screening (Currently Society for Laboratory Automation &Screening, SLAS).

His graduate and post-doctoral training was in bioanalytical chemistry and immunochemistry at the University of Arizona in Tucson, AZ. He has - 45 peer-reviewed publications and over 300 invited seminars (nationally and internationally), shor -courses and lectures in biochemical pharmacology, drug discovery assay development, tissue engineering and High Throughput Screening (HTS) and lead optimization.

sittag@mail.nih.gov

Geoffrey SIWO

My research interests range from computational biology, network science, artificial intelligence and nanotechnology.

My current research work includes developing computational methods for predicting drug resistance, open platforms for crowdsourcing computational challenges, personalizing targeted therapeutics using genomic information and designing programmable nucleic acid therapeutics or genome editing technologies. Previously, I was a lead researcher at IBM Research Africa and a co-founder of Helix Nanotechnologies, a DNA nanotechnology company. My work has been featured in several media including CNN, USA Today, Fast Company, Ozy, among other media.

MORE INFO
https://biology.nd.edu/people/geoffrey-siwo/

Ellen
‘T HOEN

Ellen ‘t Hoen (1960) is a lawyer and researcher with over 30 years of experience working on pharmaceutical and intellectual property policies. She works as an independent consultant in medicines law and policy for international organisations and governments and does research in the field of intellectual property and health.

From 1999 until 2009 she was the director of policy for Médecins sans Frontières’ Campaign for Access to Essential Medicines. In 2009 she joined WHO/UNITAID to set up the Medicines Patent Pool (MPP), an initiative that negotiates patent licenses to ensure access to affordable generic medicines in low and middle income countries. She was the MPP’s first executive director until 2012.
Since 2012 she directs Medicines Law & Policy, a group of legal and policy experts offering services to international organizations, governments and non-governmental organisations. She has been a consultant to the World Health Organization, UNITAID, Drugs for Neglected Diseases Initiative/GARDP, OXFAM, Southern African Development Community, the European Commission and the Government of the Netherlands. From 2016 to 2018 she carried out her PhD research at the Global Health Unit of the University Medical Center Groningen (UMCG), The Netherlands. She remains a researcher at the Global Health Unit at the UMCG. She was a member of the Lancet Commission on Essential Medicines Policies, and serves on the Advisory Board of Universities Allied for Essential Medicines (UAEM), the Medicines Patent Pool, and the Utrecht Centre for Affordable Biotherapeutics. She is a member of the Editorial Board of the Journal of Public Health Policy.
In 2005, 2006, 2010 and 2011 she was listed as one of the 50 most influential people in intellectual property by the journal Managing Intellectual Property.
She has published widely and is the author of several books. In 2017 she received the Prix Prescrire for her latest book “Private Patents and Public Health: Changing intellectual property rules for public health.”
She holds a Masters in Law from the University of Amsterdam and a PhD (cum laude) from the University of Groningen, The Netherlands.

Website
www.medicineslawandpolicy.org

Zelalem TEMESGEN

Dr. Zelalem Temesgen MD is an infectious diseases physician and a Professor of Medicine at Mayo Clinic, where he established and directs the Mayo Clinic HIV program and the Mayo Clinic Center for Tuberculosis. In addition to clinical responsibilities, Dr. Temesgen is actively involved in education and research both within Mayo Clinic and extramurally, domestically and internationally. He has served as the principal investigator for over 40 clinical trials including site principal investigator for a number of NIH-sponsored trials. His bibliography currently lists over 110 peer-reviewed papers, 21 book chapters, 3 indexed letters to the editor, and numerous abstracts presented at professional meetings. Dr. Temesgen is the editor-in-chief of the Clinical Journal of Tuberculosis and other Mycobacterial Diseases; Mayo Clinic Infectious Diseases Board Review Book; and Fundamentals of Global HIV Medicine.

Dr. Temesgen currently serves as the immediate past chair of the American Academy of HIV Medicine, a member of the US Department of Health and Human Services Advisory Council for the Elimination of Tuberculosis, a member of the Lancet Commission on Tuberculosis, and a member of the World Health Organization Taskforce on Digital Health for Tuberculosis. Dr. Temesgen has previously served as a member of the United States Presidential Advisory Council on HIV/AIDS as well as a member of the Scientific Advisory Board for The US President's Emergency Plan for AIDS Relief (PEPFAR).

Matthew TODD

Mat Todd was born in Manchester, England. He obtained his PhD in organic chemistry from Cambridge University in 1999, was a Wellcome Trust postdoc at The University of California, Berkeley, a college fellow back at Cambridge University, a lecturer at Queen Mary, University of London and between 2005 and 2018 was at the School of Chemistry, The University of Sydney.

He is now Chair of Drug Discovery at University College London. He lives in Greenwich, London, with his wife and two children.

Professor of Drug Discovery
SoP Pharmaceutical & Bio Chemistry
UCL School of Pharmacy

Mat's research interests include the development of new ways to make molecules, particularly how to make chiral molecules with new catalysts. He is also interested in making metal complexes that do unusual things when they meet biological molecules or metal ions. His lab motto is «To make the right molecule in the right place at the right time», and his students are currently trying to work out what this means.
He has a significant interest in open science, and how it may be used to accelerate research, with particular emphasis on open source discovery of new medicines. He founded and currently leads the Open Source Malaria (OSM) and Open Source Mycetoma (MycetOS) consortia, and is a founder of a broader Open Source Pharma movement. He is on the Editorial Boards of PLoS One, ChemistryOpen and Nature Scientific Reports.

Andrew UPDEGROVE

Andrew Updegrove is a co-founder and partner of the Boston law firm of Gesmer Updegrove LLP. Since 1988 he has worked with over 180 consortia, accredited standards development organizations and open source foundations, most of which he helped form, assisting the largest technology companies in the world. He has testified before the United States Department of Justice, Federal Trade Commission and Congressional and state committees regarding consortia and standard setting, and has filed pro bono "friend of the court" briefs with the Federal Circuit Court, Supreme Court, and Federal Trade Commission on leading standards litigation.

In 2002, he launched ConsortiumInfo.org, the most extensive resource on the Internet dedicated to consortia and standard setting, and Standards Today, a monthly e-Journal of news, ideas and analysis on standard setting that now has thousands of subscribers. The Standards Blog was added to ConsortiumInfo.org in 2005. In 2004 he was asked to join the United States Standards Strategy revision committee, received the President's Award for Journalism from the American National Standards Institute (ANSI) in 2005, and has served as a member of the Boards of Directors of ANSI, the Free Standards Group, the Linux Foundation and WorkCred, as well as on the Advisory Board of HL7. He is a graduate of Yale University and the Cornell University Law School.

John WILBANKS

John Wilbanks is the Chief Commons Officer at Sage Bionetworks. Previously, Wilbanks worked as a legislative aide to Congressman Fortney “Pete” Stark, served as the first assistant director at Harvard’s Berkman Center for Internet & Society, founded and led to acquisition the bioinformatics company Incellico, Inc., and was executive director of the Science Commons project at Creative Commons.

In February 2013, in response to a We the People petition that was spearheaded by Wilbanks and signed by 65,000 people, the U.S. government announced a plan to open up taxpayer-funded research data and make it available for free.

Wilbanks holds a B.A. in philosophy from Tulane University and also studied modern letters at the Sorbonne.

Jake
WINTERMUTE

Jake Wintermute is a long-term CRI research fellow using systems and synthetic biology to discover new drugs against tuberculosis and other human pathogens.

He holds a PhD from the Harvard department of Systems Biology, where he worked in the lab of Pam Silver. At the CRI, Jake teaches Introduction to Synthetic Biology for the AIV Master's program. He also runs an online synthetic biology course at syntheticbiology1.com.

Let’s keep in touch !

OSP3 @CRI PARTICIPANTS

Contacts

Eric ANDERSON	**Open Source Pharma Foundation (OSPF)** pollen@gmail.com
Urmi BAJPAI	**University of Delhi** urmibajpai@andc.du.ac.in
Bryn BELLOMY	**Conscience Inc.** bryn@conscience.network
Mostapha BENHENDA	**Startcrowd Online Lab** mostafacebook@gmail.com
Anshu BHARDWAJ	**Centre de Recherches Interdisciplinaires (CRI)** anshu.bhardwaj@cri-paris.org
Marc BIANCIOTTO	**Sanofi Paris** marc.bianciotto@sanofi.com
Anneke BLACKBURN	**Australian National University** anneke.Blackburn@anu.edu.au
Bruce BLOOM	**Cures Within Reach** bruce@cureswithinreach.org
Nadine BONGAERTS	**Centre de Recherches Interdisciplinaires (CRI)** nadine.bongaerts@gmail.com
Samir BRAHMACHARI	**Open Source Drug Discovery (OSDD) / AcSIR** skb@igib.in
Tanusree CHAUDHURI	**Open Source Pharma Foundation (OSPF)** tanusree.ch3@gmail.com
Wengsi CHIU	**Open Source Pharma Foundation (OSPF)** weng-si.chiu@mail.mcgill.ca
Karmen CONDIC-JURKIC	**Open Force Field Consortium** karmencj@gmail.com
Julia DANIEL	**Stanford University** jdaniel7@stanford.edu
Anjana DHAR KOUL	**Janssen** anjanad10@yahoo.com
Victoria Maria DIEZ	**Centre de Recherches Interdisciplinaires (CRI)** victoria.diez@cri-paris.org
Liesl EICHHOLZ	**Molecule** liesl@molecule.to
Keith ELLISTON	**Open Source Pharma Foundation (OSPF)** keith.elliston@ospfound.org
Nicole FOTI	**Open Insulin Project** nicole.foti@ucsf.edu

OSP3 @CRI
PARTICIPANTS

Contacts

Prateek GARG	**Open Source Pharma Foundation (OSPF)** prateek.garg16@gmail.com
Bareket GELBHART	**Gelbhart Innovations** bareket@gelbhart.com
Alina GRENIER-ARELLANO	**Open Source Pharma Foundation** alina.grenierarellano@mail.mcgill.ca
Hans HAGEN	**Institut Pasteur Paris** hans.hagen@pasteur.fr
Lee HARTWELL	**Arizona State University** lee.hartwell@asu.edu
Melanie HEARD	**Centre de Recherches Interdisciplinaires (CRI)** melanie@heard.fr
Martin HETU	**HEC Paris** martin.hetu@hec.edu
UCA JALEEL	**Open Source Pharma Foundation (OSPF)** jaleel.uc@gmail.com
Linda KAHL	**BioBricks Foundation** linda@biobricks.org
Paul KOHLHAAS	**Molecule** paul@molecule.to
Peter KOLB	**Philipps-University Marburg / DRUID** peter.kolb@uni-marburg.de
Thomas LANDRAIN	**Just One Giant Lab** thomas@JOGL.io
Ariel LINDNER	**Centre de Recherches Interdisciplinaires (CRI)** ariel.lindner@inserm.fr
Amanda McPHERSON	**Linux Foundation** amanda.mcpherson@gmail.com
Jaykumar MENON	**Open Source Pharma Foundation (OSPF) / Harvard GHI** jmenon@hsph.harvard.edu
Dusan MISEVIC	**Centre de Recherches Interdisciplinaires (CRI)** dusan.misevic@cri-paris.org
Alice MOTION	**University of Sydney** alice.motion@sydney.edu.au
Bernard MUNOS	**FasterCures** bhmunos@gmail.com

OSP3 @CRI
PARTICIPANTS

Contacts

Ganesh NEELAM	**Tata Trusts** gneelam@tatatrusts.org
Niclas NILSSON	**LEO Pharma** NNIDK@leo-pharma.com
Ole.F OLESEN	**European & Developing Countries Clinical Trials Partnership** olesen@edctp.org
Ethan PERLSTEIN	**Perlara** ethan.oren.perlstein@gmail.com
Benjamin PERRY	**DNDi** bperry@dndi.org
Massimiliano PICONE	**Fermi** max@science.cx
Colin PILLAI	**CP+ Associates** colin@cpplusassociates.org
Nibedita RATH	**Open Source Pharma Foundation (OSPF)** nibi2009@gmail.com
Guy ROULEAU	**Montreal Neurological Institute** guy.rouleau@mcgill.ca
William SCOTT	**Indiana University-Purdue University Indianapolis (IUPUI)** wscott@iupui.edu
Anne-Marie SHAND	**Taylor and Francis** annemarie.shand@informa.com
G.Sitta SITTAMPALAM	**National Institutes of Health (NIH)** gurusingham.sittampalam@nih.gov
Geoffrey SIWO	**University of Notre Dame** geoffrey.h.siwo.1@nd.edu
Ellen 'T HOEN	**Medicines Law & Policy / University Medical Centre Groningen** ellenthoen@medicineslawandpolicy.net
Zelalem TEMESGEN	**Mayo Clinic** temesgen.zelalem@mayo.edu
Matthew TODD	**University College London / Open Source Malaria** matthew.todd@ucl.ac.uk
Andy UPDEGROVE	**Gesmer Updegrove LLP** andrew.updegrove@gesmer.com
John WILBANKS	**Sage Bionetworks** wilbanks@gmail.com
Jake WINTERMUTE	**Centre de Recherches Interdisciplinaires (CRI)** ehwintermute@gmail.com

Stay connected

@OSPinfo
@criparis

#OSP3
#opensourcepharma

opensourcepharma.net
cri-paris.org